MeritValue

TRINITY BIOTECH PLC

TRIBdata completeness 88%10 fiscal years on file

Data notes: no data for concept 'epsDiluted'; no data for concept 'interestExpense'

i. The business — what you’d actually own
FigureFY 2020FY 2021FY 2022FY 2023FY 2024
Revenue$102M1$81.1M2$62.5M3$56.8M3$61.6M3
Net income−$6.39M4$875,0005−$41M6−$24M6−$31.8M6
Operating cash flow$23.8M7$13.2M8−$921,0009−$11.6M9−$4.19M9
Capital expenditure$3.18M10$1.81M11$1.1M12$803,00012$405,00012
Free cash flow (derived)$20.6M7$11.4M8−$2.02M9−$12.4M9−$4.6M9
Total debt$1.04M13————
Cash & equivalents$27.3M14$25.9M15$6.58M16$3.69M17$5.17M17
Diluted shares83.6M83.6M152.4M153.3M359.2M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.98
your share of equity
Profit it earned you last year
−$0.89
Free cash flow it threw off
−$0.13
Debt you’d be carrying
—

10 shares is a claim on −$0.98 of net worth that earned you −$0.89 and generated −$0.13 of cash last year.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
+330% shares · 5y

Share count is up 330% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 20-F · period ending 2020-12-31 · accession 0001178913-23-001916 (Revenue)
  2. 20-F · period ending 2021-12-31 · accession 0001178913-24-001486 (Revenue)
  3. 20-F · period ending 2022-12-31 · accession 0001178913-25-001835 (Revenue)
  4. 20-F · period ending 2020-12-31 · accession 0001178913-23-001916 (ProfitLossAttributableToOwnersOfParent)
  5. 20-F · period ending 2021-12-31 · accession 0001178913-24-001486 (ProfitLossAttributableToOwnersOfParent)
  6. 20-F · period ending 2022-12-31 · accession 0001178913-25-001835 (ProfitLossAttributableToOwnersOfParent)
  7. 20-F · period ending 2020-12-31 · accession 0001178913-23-001916 (CashFlowsFromUsedInOperatingActivities)
  8. 20-F · period ending 2021-12-31 · accession 0001178913-24-001486 (CashFlowsFromUsedInOperatingActivities)
  9. 20-F · period ending 2022-12-31 · accession 0001178913-25-001835 (CashFlowsFromUsedInOperatingActivities)
  10. 20-F · period ending 2020-12-31 · accession 0001178913-23-001916 (PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities)
  11. 20-F · period ending 2021-12-31 · accession 0001178913-24-001486 (PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities)
  12. 20-F · period ending 2022-12-31 · accession 0001178913-25-001835 (PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities)
  13. 20-F · period ending 2020-12-31 · accession 0001178913-21-001539 (Borrowings)
  14. 20-F · period ending 2020-12-31 · accession 0001178913-22-001759 (CashAndCashEquivalents)
  15. 20-F · period ending 2021-12-31 · accession 0001178913-23-001916 (CashAndCashEquivalents)
  16. 20-F · period ending 2022-12-31 · accession 0001178913-24-001486 (CashAndCashEquivalents)
  17. 20-F · period ending 2023-12-31 · accession 0001178913-25-001835 (CashAndCashEquivalents)